AI Article Synopsis

  • The American Tegumentary Leishmaniasis (ATL) encompasses a range of conditions caused by Leishmania protozoans, from mild cutaneous leishmaniasis (LCL) to severe forms like diffuse cutaneous leishmaniasis (DCL) and mucosal leishmaniasis (ML).
  • Research shows that senescent T cells accumulate in LCL lesions and play a key role in disease pathology, with changes in gene expression reflecting their influence.
  • The study identified a strong presence of CD8 T cell signatures and elevated senescence in LCL patients, particularly those at risk for progression to mucosal forms, offering a promising biomarker for predicting disease outcomes.

Article Abstract

The American Tegumentary Leishmaniasis (ATL) is caused by protozoans of the genus Leishmania and varies from mild localized cutaneous leishmaniasis (LCL) form to more severe manifestations such as the diffuse cutaneous leishmaniasis (DCL) form and the mucosal leishmaniasis (ML) form. Previously, we demonstrated the accumulation of senescent cells in skin lesions of patients with LCL. Moreover, lesional transcriptomic analyses revealed a robust co-induction of senescence and pro-inflammatory gene signatures, highlighting the critical role of senescent T cells in orchestrating pathology. In this work we hypothesized that senescent cells might operate differently among the ATL spectrum, potentially influencing immunopathological mechanisms and clinical outcome. We analysed previously published RNA-Seq datasets of skin biopsies of healthy subjects and lesional skin from DCL patients, LCL patients and LCL patients that, after treatment, progressed to mucosal leishmaniasis (MLP). Our findings demonstrate a robust presence of a CD8 T cell signature associated with both LCL and MLP lesions. Moreover, both inflammatory and cytotoxic signatures were significantly upregulated, showing a strong increase in MLP and LCL groups, but not DCL. The senescence signature was elevated between LCL and MLP groups, representing the only distinguishable signature of immunopathology between them. Interestingly, our analyses further revealed the senescence signature's capacity to predict progression from LCL to mucosal forms, which was not observed with other signatures. Both the senescence-signature score and specific senescence-associated genes demonstrated an increased capacity to predict mucosal progression, with correct predictions exceeding 97% of cases. Collectively, our findings contribute to a comprehensive understanding of immunosenescence in ATL and suggest that senescence may represent the latest and most important signature of the immunopathogenisis. This highlights its potential value in predicting disease severity.

Download full-text PDF

Source
http://dx.doi.org/10.1093/cei/uxae088DOI Listing

Publication Analysis

Top Keywords

mucosal leishmaniasis
12
senescent cells
12
patients lcl
12
american tegumentary
8
tegumentary leishmaniasis
8
predict progression
8
cutaneous leishmaniasis
8
lcl
8
analyses revealed
8
lcl patients
8

Similar Publications

Instrument-Free Point-of-Care Diagnostic for Leishmania Parasites.

Diagnostics (Basel)

December 2024

Biological Mimetics, Inc., 124 Byte Drive, Frederick, MD 21702, USA.

Background/objective: Leishmaniasis is the second deadliest parasitic disease in the world, after malaria, with an estimated 1.6 million new cases each year. While cutaneous leishmaniasis can result in permanent scars from lesions after treatment, the mucocutaneous and visceral diseases can result in life-altering and life-threatening complications.

View Article and Find Full Text PDF

γδ T cells play diverse roles in immune responses, producing either IL-17A or IFN-γ. Here we investigated the impact of this functional dichotomy on cutaneous leishmaniasis. We demonstrate that in Sv129 mice susceptible to Leishmania amazonensis, Vγ4+ γδ T cells are the main source of IL-17A.

View Article and Find Full Text PDF

Safety profile of miltefosine in the treatment of cutaneous leishmaniasis.

PLoS One

December 2024

Pesquisa Clínica e Políticas Públicas em Doenças Infecto-Parasitárias, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.

Cutaneous leishmaniasis (CL) is a neglected tropical disease that poses a significant public health challenge in Brazil and worldwide. Miltefosine, the only orally administered drug available for CL, was recently incorporated into Brazil's treatment protocols following recommendations by the World Health Organization (WHO) and revisions by national health authorities. While this represents an important advancement, miltefosine is associated with frequent gastrointestinal side effects and potential teratogenic risks, necessitating careful patient eligibility assessments and close clinical monitoring throughout treatment.

View Article and Find Full Text PDF

Cutaneous leishmaniasis (CL) is an endemic disease in Ethiopia, mainly caused by . Limited reports are available related to histopathological features of the skin lesion caused by . This study aimed to analyze the histopathological features of CL due to .

View Article and Find Full Text PDF

Anti-leishmanial therapies: overcoming current challenges with emerging therapies.

Expert Rev Anti Infect Ther

December 2024

Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.

Introduction: Leishmaniasis, including visceral, cutaneous, and mucocutaneous forms, present a major health challenge in tropical regions. Current antileishmanial medications has significant limitations, creating a critical need for novel therapies that are safe and cost-effective with a shorter duration of treatment.

Areas Covered: This review explores the critical aspects of existing antileishmanial therapy and targets for future therapeutic developments.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!